COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,788 Articles (22,946 medRxiv, 8,842 bioRxiv)

Most recent first Previous |  Page 1048: Articles 10471-10480  | Next

COVID MED - An Early Pandemic Trial of Losartan for Hospitalized COVID-19 Patients
Freilich, D., Victory, J., Jenkins, P., Wheeler, J., Vail, G. M., Riesenfeld, E., Cross, P., Gilmore, C., Huckabone, M., Schworm, A., Boregowda, U., Deshmukh, F., Choi, Y., Kahn, A., Gadomski, A.
10.1101/2022.01.12.22269095 — Posted: 2022-01-15
Comparison of Antibody Response Durability of mRNA-1273, BNT162b2, and Ad26.COV2.S SARS-CoV-2 Vaccines in Healthcare Workers
Brunner, W. M., Freilich, D. A., Victory, J., Krupa, N., Scribani, M. B., Jenkins, P., Lasher, E. G., Fink, A., Shah, A., Cross, P., Bush, V., Peek, L. J., Pestano, G. A., Gadomski, A. M.
10.1101/2022.01.14.22269297 — Posted: 2022-01-15
Validation of a clinical and genetic model for predicting severe COVID-19
Dite, G. S., Murphy, N. M., Spaeth, E., Allman, R., Lifelines Corona Research Initiative
10.1101/2022.01.14.22269270 — Posted: 2022-01-15
Students as Community Vaccinators: Implementation of a Service-Learning COVID-19 Vaccination Program
Griswold, A. R., Klein, J., Dusaj, N., Zhu, J., Keeler, A., Abramson, E. L., Gurvitch, D.
10.1101/2022.01.14.22269312 — Posted: 2022-01-14
Simple risk scores to predict hospitalization or death in outpatients with COVID-19
Ebell, M., Hamadani, R., Kieber-Emmons, A.
10.1101/2022.01.14.22269295 — Posted: 2022-01-14
High-cited favorable studies for COVID-19 treatments ineffective in large trials
Ioannidis, J. P. A.
10.1101/2022.01.11.22269097 — Posted: 2022-01-14 Discussion: Onsite
Evaluation and modelling of the performance of an automated SARS-CoV-2 antigen assay according to sample type, target population and epidemic trends
Yin, N., Debuysschere, C., Daubie, V., Hildebrand, M., Martin, C., Curac, S., Ponthieux, F., Payen, M.-C., Vandenberg, O., Hallin, M.
10.1101/2022.01.14.22269064 — Posted: 2022-01-14
SARS-CoV-2 Omicron Neutralization After Heterologous Vaccine Boosting
Lyke, K. E., Atmar, R. L., Dominguez Islas, C. P., Posavad, C. M., Szydlo, D., PaulChourdhury, R., Deming, M. E., Eaton, A., Jackson, L. A., Branche, A. R., El Sahly, H. M., Rostad, C. A., Martin, J. M., Johnston, C., Rupp, R. E., Mulligan, M. J., Brady, R. C., Frenck, R. W., Bäcker, M., Kottkamp, A. C., Babu, T. M., Rajakumar, K., Edupuganti, S., Dobrzynski, D., Coler, R. N., Archer, J. I., Crandon, S., Zemanek, J. A., Brown, E. R., Neuzil, K. .M., Stephens, D. S., Post, D. J., Nayak, S. U., Roberts, P. C., Beigel, J., Montefiori, D.
10.1101/2022.01.13.22268861 — Posted: 2022-01-14
The risk of SARS-CoV-2 Omicron variant emergence in low and middle-income countries (LMICs)
Bi, K., Herrera-Diestra, J. L., Bai, Y., Du, Z., Wang, L., Gibson, G., Johnson-Leon, M., Fox, S., Meyers, L. A.
10.1101/2022.01.14.22268821 — Posted: 2022-01-14
The emergence of two distinct SARS-CoV-2 Gamma related variants during the second wave of COVID-19 in Santa Catarina, Southern Brazil and the rapid spread of P.1-like-II SARS-CoV-2 variant transmission and a regionalization in the Western region
Padilha, D. A., Benetti-Filho, V., Moreira, R. S., Soratto, T. S. T., Maia, G. A., Christoff, A. P., Barazzetti, F. H., Schorner, M. A., Ferrari, F. L., Martins, C. L., Kawagoe, E. K., Wachter, J. K., Sacchet, P., Baptistella, A., Schlindwein, A. D., Coelho, B. K., Fernandes, S. B., Rovaris, D. B., dos Anjos, M. P. D., Melo, F. R., Bittencourt, B., da Cunha, S., Meneghetti, K. L., Wendt, N., Madaloz, T. Z., Rodrigues, M. V. D., Souza, D. S. M., de Moraes, M. H., Baptista, R. d. P., Toledo-Silva, G., Razzera, G., Grisard, E. C., Stoco, P. H., de Oliveira, L. F. V., Bazzo, M. L., Fongaro, G., Wagner, G.
10.1101/2022.01.13.22268697 — Posted: 2022-01-14

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).